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The use of cannabis is embedded within many societies, mostly used by the young and widely perceived to be safe. Increasing
concern regarding the potential for cannabis to cause mental health eﬀects has dominated cannabis research, and the potential
adverse respiratory eﬀects have received relatively little attention. We report a rare case of 22-year-old man who presented with
bilateral neck lymphadenopathy, fatigue, and sore throat without signiﬁcant medical or family history. The patient had smoked
one marijuana joint three times a week for three years but no cigarettes. Chest CT demonstrated a large anterior mediastinal mass
compressing the superior vena cava and mediastinal lymphadenopathy. A ﬁnal diagnosis of small-cell lung cancer was reached.
Although rare, a small-cell lung cancer in this patient should alert the physician that cannabis smoking may be a risk factor for
lung cancer.
1.Introduction
Cannabis is the most widely consumed illicit drug world-
wide, and the relationship between cannabis smoking and
lung cancer is suggestive, albeit inconclusive [1]. Cannabis
andtobaccosmokecontainasimilarmixofirritantandtoxic
chemicals, so it is suspected that cannabis and tobacco have
similar side eﬀects [2]. However, the pulmonary eﬀects of
smoking cannabis have not been extensively researched, and
the few ﬁndings are contradictory [2]. We describe a case of
small-cell lung cancer in a 22-year-old Caucasian man who
had a history of heavy short-term cannabis use.
2. Case Presentation
A 22-year-old man presented with bilateral neck lym-
phadenopathy, fatigue, and sore throat. He was treated for
presumed upper respiratory tract infection and subsequent
mononucleosis with antibiotics and a short course of
steroids,respectively,withnoimprovementofhissymptoms.
Approximately one month prior to admission, he noted per-
sistent cough, exertional dyspnea, intermittent right-sided
chest pain, hoarseness, solid food dysphagia, and facial and
neck swelling. He had no signiﬁcant medical or family
history. The patient had smoked one marijuana joint three
times a week for three years but no cigarettes. Examination
revealed tachycardia with 130 beats/minute, facial plethora,
enlarged nontender cervical neck lymphadenopathy, and de-
creased right upper lung breath sounds, suggestive of su-
perior vena cava (SVC) obstruction.
Initial chest radiograph (Figure 1) showed a large right
hilar mass with right paratracheal soft tissue mass. Chest CT
(Figure 2) demonstrated a large anterior mediastinal mass
(13cm × 6cm) compressing the SVC, right pleural eﬀusion,2 Case Reports in Medicine
Figure 1: Chest radiograph at initial presentation showing large
right hilar mass with right paratracheal soft tissue mass (see
arrows).
Figure 2: Pretreatment computed tomography of the thorax dem-
onstrating a large anterior mediastinal mass (see arrows).
and subcarinal and pericardiac lymphadenopathy. Positron
emission tomography (PET) scan conﬁrmed a hyperme-
tabolic mediastinal mass extending to the subcarinal region
and inferiorly to diaphragmatic surface along the right side
of the heart with maximum standardized uptake value of 6.5
(Figure 3). The diﬀerential diagnosis included lymphoma,
germ cell tumor, and lung cancer. Laboratory studies showed
nonreactivity for HIV, negative hepatitis B and C serology,
undetectableβ-HCG,andnormallevelsofα-fetoprotein,and
lactate dehydrogenase. Testicular ultrasound was normal.
Core biopsy of the mediastinal mass under CT guidance
contained little viable tissue due to extensive necrosis. Nev-
ertheless, immunohistochemistry (IHC) showed negativity
for lymphoid markers (CD3, TdT, CD20, PAX-5, and CD10)
and germ cell markers (AFP, PLAP, CD30, and OCT-4).
Bone marrow biopsy was normocellular. Open thoracotomy
biopsy of the mediastinal mass revealed small blue cells
with pleomorphic nuclei arranged in nests within dense
ﬁbroconnective tissue. The tumor cells exhibited features
of small-cell carcinoma: nuclear molding, high nuclear-to-
cytoplasm ratio, and ﬁne chromatin pattern/“salt and pep-
per”nuclei(Figure 4).IHCshowedstrongimmunoreactivity
with synaptophysin consistent with neuroendocrine origin
Figure 3: Positron emission tomography (PET) scan showing a
hypermetabolic mediastinal mass (see arrows).
Figure 4: The tumor cells (see arrows) exhibit features of small-
cell carcinoma: nuclear molding, high nuclear-to-cytoplasm ratio,
and ﬁne chromatin pattern/“salt and pepper” nuclei. H and E
(hematoxylin and eosin) staining.
(Figure 5), CK8/18, CK7, and weak focal immunoreactivity
for chromogranin and TTF-1. The immunostains were neg-
ative for the following markers: CD99, desmin, SMA, LCA,
vimentin, WT-1, β-HCG, and CK20. This staining pattern
conﬁrmed poorly diﬀerentiated, high-grade neuroendocrine
carcinoma, or small-cell lung cancer (SCLC).
Staging workup including PET-CT, bone scan, and brain
MRI showed no extrathoracic disease, and his disease was
considered limited stage SCLC (T4 N3 M0) as the pleural
eﬀusion showed no cytological evidence of malignant cells
and was PET-negative.
Initiation of urgent radiation therapy with cisplatin
and etoposide relieved his symptoms. The patient was free
of disease for approximately 16 months and subsequently




In 2009, there were 16.7 million (6.6% of the US population)
pastmonth users [3]. The main active chemical in marijuana
is delta-9-tetrahydrocannabinol (THC). The use of cannabisCase Reports in Medicine 3
Figure 5: Positive synaptophysin stain, consistent with neuroen-
docrine origin (see arrows).
is embedded within many societies, mostly used by the
young and widely perceived to be safe. Several studies have
shown that cannabis smoking may have a greater potential
than tobacco smoking to cause lung cancer [4, 5]. Cannabis
smoke is qualitatively similar to tobacco smoke; although
it contains 50–70% more carcinogenic hydrocarbons than
tobacco smoke [6].
Cannabis is usually smoked as a cigarette (joint) or in
a pipe. It is also smoked in blunts, which are cigars that
have been emptied of tobacco and reﬁlled with a mixture
of cannabis and tobacco. This mode of delivery combines
marijuana’s active ingredients with nicotine and other harm-
ful chemicals. Cannabis cigarettes are less densely packed
than tobacco cigarettes and tend to be smoked without ﬁlters
to a smaller butt size, leading to higher concentrations of
smoke inhaled [5, 7]. Furthermore, smokers of cannabis
inhale more deeply and hold their breath longer [8], which
further increase the lungs’ exposure to carcinogenic smoke.
These factors are likely to be responsible for the greater
absorption of carbon monoxide from cannabis joints, com-
pared with a tobacco cigarette of similar size despite similar
carbon monoxide concentrations in the smoke inhaled.
Moreover, THC causes modest short-term bronchodilation
[8]. Regular marijuana smoking produces a number of long-
term pulmonary consequences, including chronic cough and
sputum. It can cause histopathologic evidence of widespread
airway inﬂammation and injury with IHC evidence of
dysregulated growth of respiratory epithelial cells that may
beprecursorstolungcancer[8].Severalexperimentalstudies
have demonstrated precancerous histological [9–11]a n d
molecular [12] abnormalities in the respiratory tracts of
cannabis smokers.
The carcinogenic eﬀects of cannabis smoke have been
demonstrated both in vitro and in vivo models [13]. Tumors
may either directly release factors or orchestrate immune
suppressive networks by inducing host immune cell pro-
duction of inhibitory cytokines. For example, the immune
inhibitory cytokines, IL-10 and TGF-β,c a nb ep r o d u c e d
or induced by tumors, causing limitations in immune
reactivityagainstthetumor [13–15]. Conversely, there is also
evidence that THC may have anticarcinogenic eﬀects [16–
18]. Epidemiological evidence for an association between
cannabis and lung cancer is limited and conﬂicting. Case
control studies published to date have been limited by the
inability to quantify use [19], confounding with combined
cannabisandtobaccouse.Studiesundertakeninpopulations
in which use may have serious legal consequences result in
potential information bias and poor response rates [5].
At 22 years of age, this patient was quite young to be
diagnosed with small-cell lung cancer. In the United States,
there have been 0.03 cases per 1000 of lung cancer reported
in patients younger than 39 years. In this case, there was
a no cigarette smoking exposure and no known genetic
predisposition to developing lung cancer. A recent case
controlstudyfromAldingtonetal.[5]ofyoungN ewZealand
residents found that each joint-year (one joint per day for
1 year) increased the risk of lung cancer by 8%. Therefore,
smoking one joint of cannabis per day produces a similar
risk of malignancy as smoking 20 cigarettes per day [5].
This case report suggests an association between cannabis
smoking and increased risk of lung cancer. Future studies,
especially among heavy and long-term smokers of cannabis
and among nonsmokers of tobacco would be desirable to
further corroborate our results, but such populations may be
diﬃcult to ﬁnd.
4. Conclusion
From a public health perspective, physicians and patients
should be aware that smoking cannabis may be associated
with development of lung cancer. Larger studies and pooled
analysis of published data that include subjects who smoked
cannabis without tobacco are needed to evaluate the associa-
tion between use of cannabis and lung cancer.
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